SearchNewsletter
All guidelines

Obesity & weight management

4 recommendations USPSTF 2018 · AACE 2025 · ASMBS/IFSO 2022 · ACC 2025 Updated Sept. 25, 2026

Recommendations

AACE2025

Offer anti-obesity medication (eg, GLP-1 or GLP-1/GIP agents) alongside lifestyle therapy, with treatment intensity individualized to disease stage and complications rather than BMI alone (FDA-labeled use: BMI ≥30, or ≥27 with a weight-related comorbidity). The 2025 algorithm emphasizes complication-centric care and offers preferred-medication hierarchies by complication plus a lower-cost step-therapy option. Surgical therapy is outside its scope.

Verify at AACE (opens in a new tab)

ASMBS/IFSO2022

Metabolic and bariatric surgery is recommended for BMI >35 regardless of comorbidities, and should be considered for BMI 30 to 34.9 with metabolic disease. In Asian patients, BMI >25 suggests clinical obesity and surgery should be offered at BMI >27.5. Appropriately selected children and adolescents should also be considered. These criteria replace the 1991 NIH thresholds (BMI >40, or >35 with comorbidities).

Verify at ASMBS/IFSO (opens in a new tab)

ACC2025

Concise Clinical Guidance: consider obesity medication as a first-line option for eligible patients; they should not have to 'try and fail' lifestyle change first, though lifestyle therapy should always accompany it. Among FDA-approved drugs, semaglutide and tirzepatide have the highest efficacy (slightly more weight loss with tirzepatide). Evidence supports these medications reducing major adverse cardiovascular events, particularly in type 2 diabetes with elevated cardiovascular risk.

Verify at ACC (opens in a new tab)

Who this applies to

  • Adults with BMI 30 or more: offer or refer to an intensive, multicomponent behavioral program (USPSTF 2018, Grade B). BMI 25 to 29.9 with a weight-related condition also benefits (AHA, ACC and The Obesity Society 2013).
  • Medication: BMI 30 or more, or 27 or more with a weight-related complication, alongside lifestyle treatment (FDA labeling). AACE 2025 sets treatment intensity by complications rather than BMI alone, and the ACC (2025) says patients need not fail lifestyle change first.
  • Metabolic and bariatric surgery: the ASMBS and IFSO (2022) recommend it above BMI 35 regardless of comorbidity, advise considering it at 30 to 34.9 with metabolic disease, and say to offer it to Asian patients above 27.5. The older 40, or 35 with comorbidity, thresholds still appear in many payer rules.

How it is done in practice

  • Intensive means 12 or more sessions in the first year. CDC-recognized programs and dietitian-led or group programs qualify. A 5 to 10 percent loss at 6 months is the goal, and it is enough to improve glucose, blood pressure, sleep apnea and knee pain.
  • Medications and typical average loss in trials: tirzepatide about 20 percent at 72 weeks (SURMOUNT-1); semaglutide 2.4 mg weekly about 15 percent at 68 weeks (STEP 1); liraglutide 3 mg daily about 8 percent; phentermine-topiramate ER, naltrexone-bupropion and orlistat less. Phentermine alone is approved for short-term use.
  • Stopping a GLP-1 or GIP agent leads to regain of most of the weight within a year in trial extensions. Plan for long-term treatment before the first prescription, and confirm coverage, which varies widely.
  • Before starting a GLP-1 or GIP drug: personal or family history of medullary thyroid cancer or MEN2 excludes it; use caution with prior pancreatitis, gastroparesis or diabetic retinopathy; hold before anesthesia per the facility policy; stop semaglutide 2 months before a planned pregnancy.
  • Baseline: waist circumference, blood pressure, A1c, lipids, ALT. Screen for sleep apnea, fatty liver disease, depression and binge eating.

What changed recently

The 2025 AACE algorithm (obesity as adiposity-based chronic disease, managed by its complications) and the January 2025 Lancet Commission (clinical versus preclinical obesity) both move diagnosis and staging away from BMI alone. Highly effective medication moved from add-on to mainstream between 2021 and 2025, which shifted the conversation from whether to treat to how long and who pays.

Points that matter in clinic

  • Ask permission before discussing weight, then talk about function and health goals rather than the number. Weigh at every visit anyway.
  • Protein of 1.2 to 1.6 g per kg per day and resistance training protect lean mass during rapid loss, which matters most in older adults.
  • Look for contributors you can change: sleep debt, antipsychotics, insulin, sulfonylureas, beta-blockers, steroids, untreated hypothyroidism.

More quick references